Last updated: February 19, 2026
Sandostatin (octreotide) is a synthetic analog of somatostatin used in the treatment of acromegaly, carcinoid tumors, and other hormone-secreting tumors. Multiple manufacturers produce and supply this drug worldwide, often through authorized distributors or partnerships with pharmaceutical companies.
Major Manufacturers of Sandostatin
| Company |
Country |
Product Details |
Market Share |
Production Facilities |
Approval Status |
| Novartis |
Switzerland |
Brand name: Sandostatin (octreotide acetate) |
Primary global provider |
Multiple manufacturing sites globally |
Approved in over 90 countries |
| Sandoz (Novartis division) |
Switzerland |
Generic octreotide products |
Significant in generics market |
Facilities in Europe and Asia |
Approved in various jurisdictions |
| Teva Pharmaceutical Industries |
Israel |
Generic octreotide products |
Notable in global generics |
Contract manufacturing relationships |
Approved in numerous countries |
| Mylan (now part of Viatris) |
United States |
Generic octreotide analogs |
Expanding global presence |
Multiple manufacturing sites |
Approved in key markets |
| Sun Pharmaceutical Industries |
India |
Generics producer |
Growing in emerging markets |
Production units in India and abroad |
Approved in India, others pending |
Specific Supplier Networks and Distribution
1. Novartis
- Supplies the original branded version, Sandostatin, with extensive market coverage.
- Markets include North America, Europe, Asia, and Latin America.
- Partners with large distributors and hospital networks.
2. Sandoz (Subsidiary of Novartis)
- Offers biosimilar and generic versions.
- Supplies primarily in Europe and emerging markets.
- Focuses on affordability and access.
3. Teva
- Supplies generic octreotide in multiple formulations, such as injection and depot.
- Works through a global distribution network aligned with health authorities.
4. Mylan / Viatris
- Produces various bioequivalent formulations.
- Supplies primarily in North America, Europe, and Africa.
5. Sun Pharmaceutical Industries
- Offers high-volume generics, focusing on Indian and Southeast Asian markets.
- Expanding into international markets with approved products.
Regulatory and Quality Considerations
- Approved by FDA, EMA, and other major regulators for approved formulations.
- Manufacturing facilities adhere to GMP standards.
- Market authorization generally required in each country, with variations in labeling and dosage forms.
Market Dynamics and Key Players
- Novartis dominates the original branded market.
- The generics sector is highly competitive, with Teva and Mylan holding significant shares.
- Price pressures in generics drive manufacturer competition.
- Supply chains face disruptions from global logistics and regulatory shifts.
Summary
Suppliers of Sandostatin include global pharmaceuticals like Novartis, Sandoz, Teva, Mylan, and Sun Pharmaceutical Industries. Exact market share varies by region and formulation. Novartis remains the primary brand holder worldwide, with generics available from multiple manufacturers.
Key Takeaways
- Novartis is the primary global supplier of the original Sandostatin brand.
- Generics from Sandoz, Teva, Mylan, and Sun Pharmaceutical provide cost-effective alternatives.
- Regulatory approval and GMP standards are critical quality markers for suppliers.
- Market share varies geographically, with generics gaining prominence in emerging markets.
- Supply chain stability influences availability and pricing.
5 FAQs
1. Which company holds the original patent for Sandostatin?
Novartis holds the patent for octreotide and markets it under the brand name Sandostatin in major markets.
2. Are there generic alternatives to Sandostatin?
Yes, companies like Sandoz, Teva, Mylan, and Sun Pharmaceutical manufacture generic octreotide products approved in various jurisdictions.
3. How do approval standards differ across suppliers?
All approved manufacturers meet international GMP standards, but market approval depends on local regulatory processes, which can vary in strictness and requirements.
4. What regions have the highest market penetration for Sandostatin?
North America and Europe are primary markets for the branded product, while India and Southeast Asia see higher usage of generics.
5. What are the risks associated with supply chain disruptions?
Manufacturing delays, regulatory changes, and logistics issues can lead to shortages or price volatility of Sandostatin, affecting patient access and treatment continuity.
References
[1] Novartis. (2021). Sandostatin (octreotide acetate) official prescribing information. Retrieved from https://www.novartis.com
[2] U.S. Food and Drug Administration. (2022). Octreotide Injection (Sandostatin). Retrieved from https://www.fda.gov
[3] European Medicines Agency. (2022). Sandostatin (octreotide). Retrieved from https://www.ema.europa.eu
[4] IMS Health. (2022). Global pharmaceutical market data.
[5] Indian Pharmaceuticals Market Report. (2022). Sun Pharmaceuticals growth and market share analysis.
